Maraviroc

Maraviroc (Selzentry; Pfizer) is a small-molecule drug that inhibits HIV-1 entry by blocking the interaction between HIV-1 and the chemokine receptor CCR5 on host cells. It became the first drug in its class to be approved by the US FDA for the treatment of patients with CCR5-tropic HIV-1 in combination with other antiretroviral agents in August 2007, and it was approved in Europe (where its trade name is Celsentri) in September 2007.